Overview
Optimizing Medical Management Post-Revascularization: A Case Review
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this activity, expert faculty give their multidisciplinary perspectives in vascular surgery and cardiology regarding recommendations for patients with peripheral artery disease (PAD) post-revascularization. These patients are at risk for further complications and may be eligible for additional therapy. Dr. Marc Bonaca and Dr. Alan Dietzek relay practice implications of the latest guidelines and data across the various agents and combinations for patients with PAD.
This activity is intended for vascular surgeons, interventional cardiologists, clinical cardiologists, and other healthcare providers who care for patients with peripheral vascular disease.
Because US peripheral artery disease (PAD) guidelines have not yet been updated, clinicians may not yet be familiar with the groundbreaking VOYAGER PAD study just published in May 2020 which showed that the addition of rivaroxaban to aspirin reduced risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. It is critical for vascular surgeons, interventional cardiologists, and other healthcare providers who care for patients with PAD to understand the latest data to ensure that their patients receive the best possible care and mitigate further complications.
Upon completion of this activity, participants will be able to:
• Optimize anticoagulant therapy in patients with PAD post-revascularization
• Discuss limitations of various guideline recommendations for patients with PAD post-revascularization in the context of recent evidence
• Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for patients with PAD post-revascularization
• Optimize anticoagulant therapy in patients with PAD post-revascularization
• Discuss limitations of various guideline recommendations for patients with PAD post-revascularization in the context of recent evidence
• Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for patients with PAD post-revascularization
This activity is sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
Marc Bonaca, MD, MPH
Executive Director, CPC
Professor of Medicine, Cardiology, and Vascular Medicine
Director of Vascular Research
University of Colorado School of Medicine
Aurora, CO
Executive Director, CPC
Professor of Medicine, Cardiology, and Vascular Medicine
Director of Vascular Research
University of Colorado School of Medicine
Aurora, CO
Alan M. Dietzek, MD, RPVI
Clinical Professor of Surgery
University of Vermont College of Medicine
Network Chief, Vascular and Endovascular Surgery
Linda and Stephen R. Cohen Chair in Vascular Surgery
Western Connecticut Health Network
Danbury, CT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Marc Bonaca, MD, MPH
Consultant: Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, Novo Nordisk, Pfizer
Grants (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, Novo Nordisk, Pfizer
Alan M. Dietzek, MD, RPVI
No relationships to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.